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Interventional Cardiology
DES or BMS: Effect on Quality of Life
Garg and colleagues designed a Markov model to explore the effects onquality-adjusted life expectancy of choosing drug-eluting stents (DES)
versus bare-metal stents (BMS). The model attempts to answer the question:
what excess risk of late stent thrombosis with DES would be an acceptable
tradeoff for suppressing restenosis compared with BMS? Data regarding the
relative and absolute risks of DES, BMS, and secondary procedures, and the
effect of these outcomes on quality of life were compiled from a wide variety of
published studies. The models indicate that if the excess risk of very late stent
thrombosis is 0.14% per year over 4 years, most patients would prefer DES
to BMS. This article may help physicians more effectively compare the risks
and benefits of DES. See pages 1844 and 1854. See figure.
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Myocardial Infarction
New ANP Biomarker Assay Helps Predict Acute MI Mortality
While B-type natriuretic peptide (BNP) is well validated as a post-myocardial infarction (MI) risk stratifier, the initial studies with atrial
natriuretic peptide (ANP) were less compelling. Khan and colleagues noted
that the ends of ANPmay be degraded by proteases, and therefore developed an
assay that recognizes epitopes in the mid-region of the ANP prohormone
(MR-proANP), an area that is less likely to degraded. Levels of MR-proANP
and N-terminal (NT)-proBNP were analyzed 3 to 5 days after the onset of
chest pain in almost 1,000 persons who suffered an MI and were then followed
for up to 2 years. Levels of both assays were higher in patients who died than in
those who survived; the highest risk was in patients in the upper quartile for
both measurements. MR-proANP is a useful risk stratifier, especially in those
with an elevated NT-proBNP. See page 1857. See figure.
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Heart Failure
Measuring BNP Precursor Peptide May Improve Diagnostic Accuracy
The initial translation and processing of the B-type natriuretic peptide(BNP) messenger ribonucleic acid results in an 108 amino acid peptide
denoted as proBNP. ProBNP is then further cleaved into two fragments: BNP,
a vasoactive 32 amino acid peptide, and the N-terminal peptide fragment
(NT-proBNP). The currently available assays for BNP and NT-proBNP likely
cross react with proBNP in the serum. This study by Waldo and colleagues
used 3 different assays to measure proBNP, BNP, and NT-proBNP in patients
with decompensated heart failure. The proBNP levels were not affected by
body mass index (BMI), renal function, or age. All 3 peptides were significantly
elevated in patients who died within 90 days. This preliminary comparison
suggests that NT-proBNP has a slightly higher diagnostic yield for predicting
death, but the apparent lack of interference with BMI, renal dysfunction, and
age suggests that proBNP should be further studied. See page 1874.
See figure.
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Heart Failure
ET Does Not Cause Long-Term Changes in Myocardial Energy Metabolism
Reductions in phosphocreatine and adenosine triphosphate have been implicatedin the altered myocardial energy metabolism that contributes to contractile
dysfunction. High energy phosphate metabolism can be measured by 31P-MR spec-
troscopy (MRS). Beer and colleagues performedMRS on patients with non-ischemic
cardiomyopathies to study the effect of an intensive exercise training (ET) program for
2months. The ET improved peak VO2, left ventricular (LV) end-systolic volume, and
LV ejection fraction. The improvement in cardiac function was not accompanied by
changes in cardiac high-energy phosphate concentrations. This study demonstrates
that ET can produce substantial improvements in exertional capacity without an effect
on myocardial energy metabolism; this lack of effect may be beneficial, as other
modalities that stimulate the myocardium may deplete myocardial energy stores and
increase mortality. See pages 1883 and 1892. See figure.
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Hypertension
Evidence that Cardiac Autonomic Dysfunction Precedes Hypertension
This study byWu and colleagues examined the hypothesis that cardiac autonomicfunction (CAF) is altered in pre-hypertensive subjects and those with a family
history of hypertension (FHH). Nearly 1,500 subjects were classified as having nor-
motension (120/80 mmHg), pre-hypertension (120 to 139/80 to 89 mmHg), or
hypertension (140/90 mm Hg). Cardiac autonomic function was determined by
multiple methods, including standard deviation of RR interval, the heart rate variabil-
ity with standing, and respiratory variation in the heart rate. There was a significant,
graded difference in all CAF indexes along the spectrum of hypertension. This study
provides evidence thatCAFplays a role inpre-hypertension and that altered autonomic
function is already present in subjects with FHH. See pages 1896 and 1902.
See figure.
